Pay in 4 interest-free payments of $29.75 Learn more
Ships within 48 hours · Estimated delivery Aug 1 - Aug 6
The drug-treated groups reveal lower expression of p-STAT3 compared to the CAC group
3)11-5-9(4-10(7-16)8-17)6-12(15)13(11)18/h4-6
Br J Pharmacol
Formula: C27H29N5
TGFβRI-IN-2 (compound 18) at 1 μM shows a 31% inhibition of MAP3K2 (MEKK2) with an IC50 value of 2
MI-192 nt 1 The drug-treated groups reveal lowerMI 192 is a histone deacetylases (HDACs) inhibitor that preferentially inhibits HDAC2 and HDAC3 with IC50 values of 30 nM and 16 nM, respectively . Histone acetylation is the most commonly employed mechanism utilized by transcription factors to activate gene expression. Conversely, histone deacetylation is the most common mechanism used to inactivate genes. Histone deacetylase inhibitors (HDACIs) are in advanced clinical development as cancer
US$ 199.50
US$ 650.00
US$ 153.00
US$ 161.50
US$ 194.00
US$ 2362.50
US$ 637.50
US$ 138.50
US$ 209.50
US$ 135.00
US$ 258.00
US$ 225.97
US$ 379.50
US$ 216.47
US$ 211.97